Biogen said it will incur a $46M charge in its Q2 results leading to a ($0.26) impact in its GAAP and non-GAAP EPS due to acquired in-process research and development (IPR&D), upfront, and milestone ...
In a regulatory filing, the company stated, “Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2025 are expected to include acquired IPR&D and milestones expense of $2.7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback